Artiva Biotherapeutics (ARTV) Accumulated Expenses (2023 - 2026)

Artiva Biotherapeutics (ARTV) has reported Accumulated Expenses for 4 consecutive years, with $3.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses fell 50.07% year-over-year to $3.2 million; the TTM figure through Mar 2026 stood at $3.2 million (down 50.07% YoY), while the FY2025 annual figure was $9.6 million, up 98.72% from the prior year.
• Accumulated Expenses eased to $3.2 million in Q1 2026 per ARTV's latest filing, from $9.6 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $9.6 million in Q4 2025 and bottomed at $3.2 million in Q1 2026.
• Historically, Accumulated Expenses has averaged $6.0 million across 4 years, with a median of $5.8 million in 2025.
• Annual changes were most pronounced in 2025 — Accumulated Expenses soared 98.72% — and 2026, when it slumped 50.07%.
• Artiva Biotherapeutics' Accumulated Expenses stood at $4.0 million in 2023, then advanced by 19.37% to $4.8 million in 2024, then jumped by 98.72% to $9.6 million in 2025, then sank by 66.84% to $3.2 million in 2026.
• Business Quant data shows ARTV's Accumulated Expenses at $3.2 million in Q1 2026, $9.6 million in Q4 2025, and $5.6 million in Q3 2025.